Prostate cancer is the most common cancer among men, but it can often be treated successfully if found early. In fact, about 1 man in 6 will be diagnosed with prostate cancer during his lifetime. Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.
The most common method of detecting prostate cancer currently is by measuring prostate-specific antigen (PSA) levels. Along with other clinical considerations, if a man's PSA level is high, he may be a candidate for biopsy to determine whether or not he has prostate cancer. However, PSA is only prostate-specific and not cancer-specific. This means that other conditions, such as urinary tract infection and riding a bike, can result in elevated PSA levels. As a result, only 25% of men who have a high PSA level between 4.0 and 10 ng/mL will have prostate cancer and thus, will have undergone an unnecessary painful biopsy procedure.
We at Cleveland Diagnostics are developing a blood-based assay to more effectively and accurately investigate prostate cancer biomarkers based on structure, not concentration.